More than 10 disease-modifying therapies (DMT) are approved by the European Medicines
Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of multiple …

Occurrence of pulmonary arterial hypertension (PAH) in idiopathic inflammatory myopathies
(IIMs) without extensive interstitial lung disease (ILD) has rarely been described in the …

Although rare in its idiopathic form, pulmonary arterial hypertension (PAH) is not uncommon
in association with various associated medical conditions, most notably connective tissue …

Background No population-based study has investigated the cumulative incidence of
pulmonary arterial hypertension (PAH) in patients with newly diagnosed systemic lupus …

Although further research into treatment strategies for the pulmonary complications seen in
SLE and pSS is needed, the clinician should be aware of the risk factors and clinical …

Pulmonary hypertension (PH) is a rare but life-threatening condition in antiphospholipid
syndrome (APS) patients with or without systemic lupus erythematosus (SLE). The definition …

Connective tissue diseases (CTDs) comprise several immunologic systemic disorders, each
of which associated with a particular set of clinical manifestations and autoimmune profile …

Objectives This study aims to identify the factors associated with the development and
mortality of pulmonary hypertension (PH) in systemic lupus erythematosus (SLE) patients …

Lung involvement in connective tissue disorders (CTDs) may present as pleomorphic since
any lung compartment may be involved such as airways, exocrine secretory and alveolar …

Systemic lupus erythematosus (SLE) and antiphospholipid antibody syndrome (APALS) are
multisystemic autoimmune disorders that can involve different parts of the pulmonary system …